首页> 美国卫生研究院文献>Journal of the Endocrine Society >The Clinical Significance and Utility of Routine Screening for Macroprolactin in Patients With Hyperprolactinemia
【2h】

The Clinical Significance and Utility of Routine Screening for Macroprolactin in Patients With Hyperprolactinemia

机译:高催乳素血症患者Macropolactin常规筛选常规筛选的临床意义及效用

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Background: Macroprolactin is a complex of monomeric prolactin (PRL) molecules with immunoglobulin G (IgG) that can result in the elevation of serum prolactin level. Macroprolactin is biologically less active and failure to screen for macroprolactin may lead to unnecessary investigations and treatments in patients with hyperprolactinaemia. Aim: We sought to evaluate the clinical significance and clinical utility of routine screening of macroprolactin in patients with hyperprolactinemia. Methods: We analysed 141 patients from a retrospective database of patients with elevated serum prolactin in Changi General Hospital from Jan 2017 to Dec 2019 with routine screening of macroprolactin with polyethylene glycol (PEG) precipitation using Abbott Architect Prolactin assay. Clinical, biochemical, radiological data and medication usage were extracted from electronic medical records. Macroprolactinaemia was defined as a PRL recovery of < 60%. Approval was obtained from the local research ethics committee. Results: Thirty-six (26%) patients had macroprolactinaemia with a male predominance (72%). There were no significant differences in the presence of symptoms, the percentages of medication-induced hyperprolactinemia, and magnetic resonance imaging (MRI) pituitary scans done between patients with macroprolactinaemia and those with truly elevated serum prolactin. As such clinical features might not be useful to differentiate patients with macroprolactinaemia. Eight MRI pituitary scans were performed in patients with macroprolactinaemia and pituitary abnormalities were detected in 4 of the patients which are likely non-functioning pituitary lesions. As such, not only were unnecessary scans done but it also led to a cascade of further investigations. Eight patients had simultaneous macroprolactinaemia and elevated bioactive serum prolactin, as such post-PEG prolactin level with corresponding reference ranges rather than the percentage recovery should be use as the threshold for defining macroprolactinaemia to avoid misdiagnosis. Conclusion: Macroprolactinaemia is common and routine screening may avert unnecessary investigations. Post-PEG prolactin level with corresponding reference ranges should be used as diagnostic threshold.
机译:背景:Macroplachactin是具有免疫球蛋白G(IgG)的单体催乳素(PRL)分子的复合物,其可导致血清催乳素水平的升高。 Macroplactin在生物学上较低,活性较低,未筛选Macroplactin可能导致高术式血症患者的不必要的研究和治疗。目的:我们试图评估常规癌症患者Macroplactin常规筛查常规筛查的临床意义和临床效用。方法:从2017年1月到2019年1月,分析了141例从樟宜常规医院血清催乳素升高的患者患者的患者,使用Abbott Architect催乳素测定常规筛选Macroplactin的常规筛选Macroplactin。从电子病历中提取临床,生化,放射数据和药物用途。 Macroplactina血症定义为<60%的PRL回收率。批准从当地的研究伦理委员会获得。结果:36名(26%)患者患有Macroplactina血症,具有男性优势(72%)。存在症状的存在,药物诱导的高催乳素血症的百分比和磁共振成像(MRI)垂体扫描在Macropolactina血症患者和真正升高的血清催乳素患者之间进行的脑垂体扫描的百分比没有显着差异。由于此类临床特征可能对鉴别患者患有Macropolactina血症的患者来说不有用。八个MRI垂体扫描在患者中进行Macroplactina血症和垂体异常检测到4个可能是非功能性垂体病变的患者。因此,不仅是不必要的扫描,而且它也导致了进一步的进一步调查。八名患者具有同时的Macroplactina血症和升高的生物活性血清催乳素,因为这种PEG催乳素水平具有相应的参考范围而不是百分比恢复应该用作定义Macroplactina血症以避免误诊的阈值。结论:Macroplactina血症是常见的,常规的筛查可能避免不必要的调查。 PEG后PEG催乳素水平应使用相应的参考范围用作诊断阈值。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号